Skip to main content

Breast Cancer Research and Treatment

Ausgabe 2/2009

Inhalt (22 Artikel)

Review

The fertility-related concerns, needs and preferences of younger women with breast cancer: a systematic review

Michelle Peate, Bettina Meiser, Martha Hickey, Michael Friedlander

Review

The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer

Tyler Lahusen, Ralf T. Henke, Benjamin L. Kagan, Anton Wellstein, Anna T. Riegel

Preclinical Study

Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal–epithelial interactions

Osvaldo Pontiggia, Vanina Rodriguez, Victoria Fabris, Diego Raffo, Viviana Bumaschny, Gabriel Fiszman, Elisa Bal de Kier Joffé, Marina Simian

Preclinical Study

Three-dimensional pathological size assessment in primary breast carcinoma

Uwe Güth, Denise Brenckle, Dorothy Jane Huang, Andreas Schötzau, Carsten Thomas Viehl, Holger Dieterich, Wolfgang Holzgreve, Edward Wight, Gad Singer

Preclinical Study

Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer

Maurice P. H. M. Jansen, Kirsten Ruigrok-Ritstier, Lambert C. J. Dorssers, Iris L. van Staveren, Maxime P. Look, Marion E. Meijer-van Gelder, Anieta M. Sieuwerts, Jozien Helleman, Stefan Sleijfer, Jan G. M. Klijn, John A. Foekens, Els M. J. J. Berns

Preclinical Study

Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition

Frank Köster, Jörg B. Engel, Andrew V. Schally, Arnd Hönig, Andreas Schröer, Stephan Seitz, Florian Hohla, Olaf Ortmann, Klaus Diedrich, Stefan Buchholz

Preclinical Study

Immortalization and transformation of human mammary epithelial cells by a tumor-derived Myc mutant

Clare A. Thibodeaux, Xuefeng Liu, Gary L. Disbrow, Yiyu Zhang, Janice D. Rone, Bassem R. Haddad, Richard Schlegel

Preclinical Study

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study

Stella Mook, Marjanka K. Schmidt, Giuseppe Viale, Giancarlo Pruneri, Inge Eekhout, Arno Floore, Annuska M. Glas, Jan Bogaerts, Fatima Cardoso, Martine J. Piccart-Gebhart, Emiel T. Rutgers, Laura J. van’t Veer

Clinical Trial

The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy

Yi Zhang, Anieta M. Sieuwerts, Michelle McGreevy, Graham Casey, Tanja Cufer, Angelo Paradiso, Nadia Harbeck, Paul N. Span, David G. Hicks, Joseph Crowe, Raymond R. Tubbs, G. Thomas Budd, Joanne Lyons, Fred C. G. J. Sweep, Manfred Schmitt, Francesco Schittulli, Rastko Golouh, Dmitri Talantov, Yixin Wang, John A. Foekens

Clinical trial

Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity

Giuseppe Viale, Nicole Rotmensz, Patrick Maisonneuve, Luca Bottiglieri, Emilia Montagna, Alberto Luini, Paolo Veronesi, Mattia Intra, Rosalba Torrisi, Anna Cardillo, Elisabetta Campagnoli, Aron Goldhirsch, Marco Colleoni

Clinical trial

A small subgroup of operable breast cancer patients with poor prognosis identified by quantitative real-time RT-PCR detection of mammaglobin A and trefoil factor 1 mRNA expression in bone marrow

Kjersti Tjensvoll, Bjørnar Gilje, Satu Oltedal, Victor F. Shammas, Jan Terje Kvaløy, Reino Heikkilä, Oddmund Nordgård

Clinical Trial

A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease

Thomas E. Rohan, Abdissa Negassa, Rowan T. Chlebowski, Clementina D. Ceria-Ulep, Barbara B. Cochrane, Dorothy S. Lane, Mindy Ginsberg, Sylvia Wassertheil-Smoller, David L. Page

Clinical trial

Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial

S. Del Barco, R. Colomer, L. Calvo, I. Tusquets, E. Adrover, P. Sánchez, J. Rifà, J. De la Haba, J. A. Virizuela

Clinical Trial

Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy

Marco Colleoni, Vincenzo Bagnardi, Nicole Rotmensz, Richard D. Gelber, Giuseppe Viale, Giancarlo Pruneri, Paolo Veronesi, Rosalba Torrisi, Anna Cardillo, Emilia Montagna, Elisabetta Campagnoli, Alberto Luini, Mattia Intra, Viviana Galimberti, Eloise Scarano, Giulia Peruzzotti, Aron Goldhirsch

Open Access Clinical Trial

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial

Matthew J. Ellis, William R. Miller, Yu Tao, Dean B. Evans, Hilary A. Chaudri Ross, Yasuhiro Miki, Takashi Suzuki, Hironobu Sasano

Epidemiology

BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research

Susan L. Neuhausen, Hilmi Ozcelik, Melissa C. Southey, Esther M. John, Andrew K. Godwin, Wendy Chung, Jeniffer Iriondo-Perez, Alexander Miron, Regina M. Santella, Alice Whittemore, Irene L. Andrulis, Saundra S. Buys, Mary B. Daly, John L. Hopper, Daniela Seminara, Ruby T. Senie, Mary Beth Terry

Epidemiology

Complementary and alternative therapies among very long-term breast cancer survivors

C. L. Carpenter, P. A. Ganz, L. Bernstein

Epidemiology

CHEK2 1100delC and male breast cancer in the Netherlands

Marijke Wasielewski, Michael A. den Bakker, Ans van den Ouweland, Marion E. Meijer-van Gelder, Henk Portengen, Jan G. M. Klijn, Hanne Meijers-Heijboer, John A. Foekens, Mieke Schutte

Epidemiology

Dietary isoflavone intake and breast cancer risk in case–control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians

Motoki Iwasaki, Gerson Shigeaki Hamada, Ines Nobuko Nishimoto, Mario Mourão Netto, Juvenal Motola Jr., Fábio Martins Laginha, Yoshio Kasuga, Shiro Yokoyama, Hiroshi Onuma, Hideki Nishimura, Ritsu Kusama, Minatsu Kobayashi, Junko Ishihara, Seiichiro Yamamoto, Tomoyuki Hanaoka, Shoichiro Tsugane

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.